Lopez de Rodas, Miguel http://orcid.org/0000-0002-6062-4064
Schalper, Kurt A. http://orcid.org/0000-0001-5692-4833
Article History
First Online: 23 September 2021
Competing interests
: K.A.S. has received research funding from AstraZeneca, Bristol Myers Squibb, Eli Lilly, Merck Sharpe & Dohme, Moderna, Navigate Biopharma, Pierre Fabre, Ribon Therapeutics, Surface Oncology, Takeda–Millenium Pharmaceuticals and Tesaro–GSK; and honoraria for consultancy, advisory or speaker roles from Agenus, Bristol Myers Squibb, Clinica Alemana de Santiago, EMD Serono, Fluidigm, Genmab, Merck Sharpe & Dohme, PeerView, Pierre Fabre, Shattuck Labs, Takeda–Millenium Pharmaceuticals and Torque Therapeutics. M.L.d.R. declares no competing interests.